Foscarbidopa/Foslevodopa Therapy Improves Continuous Duration of Good ON Time and Correlated With Quality of Life in People With Parkinson’s Disease
Objective: To assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on longest consecutive duration of Good and Best ON time and association of…Exploring Clinical and Neurophysiologic Predictors of Adaptive Deep Brain Stimulation Response in Parkinson’s disease
Objective: To evaluate clinical and neurophysiologic characteristics that may predict a positive clinical response to adaptive deep brain stimulation (aDBS) in patients previously stable on…GT-02287 in Parkinson’s Disease: Interim Data from a Phase 1b Study
Objective: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the brain-penetrant glucocerebrosidase (GCase) modulator GT-02287 in people with Parkinson’s disease with and without a…Evaluation of Local Field Potential-guided DBS-programming in a Parkinson’s disease outpatient clinic
Objective: To evaluate potential use and applicability of local field potential-guided DBS-programming under real-life conditions in a Parkinson’s disease (PD) outpatient clinic. Background: Deep brain…Effects of Dynamic Neuro-Cognitive Imagery on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial
Objective: To compare the effects of an experimental intervention (EI) based on DNI with a control intervention (CI) of equal volume and intensity, excluding MP…Quercetin Reduces mtDNA Release in PRKN-Deficient and Oxidatively Stressed SH-SY5Y Cells
Objective: This study investigates the role of Parkin deficiency in mitochondrial dysfunction and its contribution to mitochondrial DNA (mtDNA) release in Parkinson’s disease (PD). We…Clinical Progression and Genetic Pathways in Body-First and Brain-First Par-kinson’s Disease
Objective: We aim to assess Parkinson's disease (PD) phenotypes across both prodromal and clinical PD stages, track their pathological progression in vivo and identify potential underlying…The Effectiveness of Rivastigmine in Parkinson’s Disease: Impact on Motor Symptoms, Gait, Cognitive Function, and Falls – A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs
Objective: To evaluate the efficacy of rivastigmine in patients with Parkinson’s disease (PD) by assessing its impact on motor symptoms, cognitive function, gait, falls, and…Design of ORCHESTRA Study: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease
Objective: To describe the practical management of foslevodopa/foscarbidopa (LDp/CDp) for treating advanced Parkinson’s disease (aPD) in routine clinical practice using data collected through a patient…Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…
- « Previous Page
- 1
- …
- 178
- 179
- 180
- 181
- 182
- …
- 553
- Next Page »